Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Pretargeted radioimmunotherapy (PRIT) using an anti-CD45 antibody (Ab)–streptavidin (SA) conjugate and DOTA-biotin labeled with β-emitting radionuclides has been explored as a strategy to decrease relapse and toxicity. α-emitting radionuclides exhibit high cytotoxicity coupled with a short path leng...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Pagel, John M., Kenoyer, Aimee L., Bäck, Tom, Hamlin, Donald K., Wilbur, D. Scott, Fisher, Darrell R., Park, Steven I., Frayo, Shani, Axtman, Amanda, Orgun, Nural, Orozco, Johnnie, Shenoi, Jaideep, Lin, Yukang, Gopal, Ajay K., Green, Damian J., Appelbaum, Frederick R., Press, Oliver W.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2011
Onderwerpen:
Myeloid Neoplasia
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3142907/
https://ncbi.nlm.nih.gov/pubmed/21613259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-347039
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items